CALCA and Parkinson disease: Given that many of the above hypotheses are extrapolations from other neurodegenerative disorders and pathological processes, we are currently pursuing a study supported by the Alzheimer’s Association, and planned to be completed in late 2025, on CGRP-related pathways in the development and progression of Clinicopathologically-established Parkinson’s Disease (CGRP in CPPD), in order to better establish whether CGRP and its downstream effects are indeed associated with PD pathology across dynamic (sleep–wake) cycles and across disease stages.